Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)
Status: | Recruiting |
---|---|
Conditions: | Hospital, Neurology |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/1/2019 |
Start Date: | December 4, 2017 |
End Date: | August 2020 |
Contact: | Katie Quinlan |
Email: | kquinla4@jhmi.edu |
Phone: | 443-287-9591 |
AVERT is a randomized controlled trial comparing video-oculography (VOG)-guided care to
standard care to assess accuracy of diagnoses and initial management decisions for emergency
department (ED) patients with a chief symptom of vertigo or dizziness suspected to be of
vestibular cause. The trial will test the hypothesis that VOG-guided rapid triage (VRT) will
accurately, safely, and efficiently differentiate peripheral from central vestibular
disorders in ED patients presenting acute vertigo or dizziness, and that doing so has the
potential to improve post-treatment clinical outcomes for these patients.
standard care to assess accuracy of diagnoses and initial management decisions for emergency
department (ED) patients with a chief symptom of vertigo or dizziness suspected to be of
vestibular cause. The trial will test the hypothesis that VOG-guided rapid triage (VRT) will
accurately, safely, and efficiently differentiate peripheral from central vestibular
disorders in ED patients presenting acute vertigo or dizziness, and that doing so has the
potential to improve post-treatment clinical outcomes for these patients.
AVERT is a multicenter, Phase II clinical trial comparing a novel diagnostic strategy (VRT)
to standard ED diagnostic care at three performance sites. The Specific Aims are to assess
diagnostic accuracy, diagnostic workup costs, and estimate the short-term impact of correct
diagnosis in anticipation of a larger, definitive Phase III trial. Adult ED patients with a
chief symptom of vertigo, dizziness, or unsteadiness, new or clearly worse in the previous 30
days, will undergo on-site vestibular function tests by trained research personnel using a
portable, quantitative VOG recording device. Research personnel will also record a focused
symptom history and bedside hearing tests. Eligible patients with at least one pathologic
vestibular eye movement finding or pathologic ataxia will be randomized to VRT or standard ED
care. Patients eligible for pre-randomization testing but excluded from randomization will be
slated for the Observational Arm of the study and will undergo limited 1 and 6 month phone
follow-up. The VRT arm relies on an automated algorithm to interpret VOG results, thereby
determining a patient-specific clinical care pathway. For safety, all VRT-arm study subjects
will undergo stroke protocol MRI before release. All randomized subjects will undergo
confirmatory testing at one week, including vestibular specialist exam and 3-Tesla research
MRI combining stroke and internal auditory canal protocols. All randomized patients will also
undergo 1 month and 6 month phone follow-up and medical record review to confirm diagnoses.
Clinical findings, ED diagnoses, diagnostic resource utilization, treatments applied, and
clinical events during follow-up will be recorded. A multidisciplinary, masked, expert panel
will adjudicate final diagnoses.
to standard ED diagnostic care at three performance sites. The Specific Aims are to assess
diagnostic accuracy, diagnostic workup costs, and estimate the short-term impact of correct
diagnosis in anticipation of a larger, definitive Phase III trial. Adult ED patients with a
chief symptom of vertigo, dizziness, or unsteadiness, new or clearly worse in the previous 30
days, will undergo on-site vestibular function tests by trained research personnel using a
portable, quantitative VOG recording device. Research personnel will also record a focused
symptom history and bedside hearing tests. Eligible patients with at least one pathologic
vestibular eye movement finding or pathologic ataxia will be randomized to VRT or standard ED
care. Patients eligible for pre-randomization testing but excluded from randomization will be
slated for the Observational Arm of the study and will undergo limited 1 and 6 month phone
follow-up. The VRT arm relies on an automated algorithm to interpret VOG results, thereby
determining a patient-specific clinical care pathway. For safety, all VRT-arm study subjects
will undergo stroke protocol MRI before release. All randomized subjects will undergo
confirmatory testing at one week, including vestibular specialist exam and 3-Tesla research
MRI combining stroke and internal auditory canal protocols. All randomized patients will also
undergo 1 month and 6 month phone follow-up and medical record review to confirm diagnoses.
Clinical findings, ED diagnoses, diagnostic resource utilization, treatments applied, and
clinical events during follow-up will be recorded. A multidisciplinary, masked, expert panel
will adjudicate final diagnoses.
Inclusion criteria:
Adult (18 years and older) ED patients with all of the following (all determined
pre-randomization):
VESTIBULAR SYMPTOMS: presenting symptom of "vertigo" OR "dizziness" OR "unsteadiness" (as
defined by consensus expert definitions in the International Classification of Vestibular
Disorders).
RELEVANT EXAM SIGNS*: pathologic nystagmus (spontaneous, gaze-evoked, or positional) by
bedside VOG testing OR pathologic ataxia (gait, trunk, stance, limbs) by bedside ataxia
examination.
RECENT ONSET: symptoms AND signs* appear to be new or markedly worse in the past month
* Exam signs are required for randomization, but not for the observational arm
Exclusion Criteria
1. Excluded from Pre-Randomization Screening
Level 1 trauma or critical illness Altered mental status (e.g., delirium, dementia)
that would preclude active study participation (this includes patients with abnormal
mental state due to alcohol intoxication or illicit substance, which are known,
easily-recognized causes of dizziness or vertigo presentations to the ED) Non-English
speaking (enrollment of non-English speakers is not feasible given the logistics of
identifying a translator and the need for rapid recruitment and randomization in the
AVERT study; furthermore, the terms vertigo, dizziness, and unsteadiness may have
different meanings in other languages) Known pregnancy (all women of childbearing age
who are enrolled will undergo a urine or serum beta-HCG pregnancy test prior to MRI to
confirm no pregnancy, per local institutional guidelines)
Unable or unsafe to participate in screening, including VOG tests (as deemed by
specific pre-enrollment risk assessment questions or ED provider and/or Study
Coordinator judgment) including, but not limited to:
visual impairment sufficient to prevent visual fixation during the VOG testing
clinically-perceived risk to patient of participating in study (ED provider or staff
concerns) clinically-perceived risk to research staff (e.g., violence, blood/body
fluid/respiratory precautions) unstable cardiac status (given a single reported case
of bradycardia with impulse testing) acute cranio-cervical trauma or other condition
(e.g., rheumatoid arthritis) that might lead to instability of the cervical spine that
would be a contraindication to neck rotation during VOG testing Obvious general
medical cause (as judged by treating ED provider) including, but not limited to, acute
myocardial infarction, pulmonary embolus, pneumonia, urinary tract infection, drug
intoxication, etc.
2. Excluded from Randomization (Eligible for Observational Arm Follow-up)
Patient previously randomized in the AVERT Trial (previously screened but not randomized
are eligible)
Unable to participate fully with study follow-up (particularly MRI) including, but not
limited to:
unable to return for follow-up testing within 30 days unable to undergo MRI because of
contraindications (e.g., pacemaker, metallic foreign body, pregnancy) or other reasons
(severe claustrophobia, too large or too heavy for MRI scanner)
We found this trial at
2
sites
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
Click here to add this to my saved trials